Pfizer Inc. today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, ...

Enhancing the speed and efficiency of clinical trial recruitment is a key objective across international health systems. This study aimed to use artificial intelligence (AI) applied in the Victorian ...

For the multifaceted and complex diseases, multi-omics could define groups of patients with distinct endotypes exhibiting heterogeneous treatment responses due to their particular underlying molecular ...

State Key Laboratory of Advanced Processing and Recycling of Nonferrous Metals, Lanzhou University of Technology, Lanzhou 730050, China ...

Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. Its cis-binding mechanism is claimed to improve T reg-depletion ...

Activating agents enable the efficient preparation of organozinc complexes from zinc metal and organohalides, but their mechanisms had been obscured by the heterogeneous nature of these systems.

From Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville Campus, Victoria, Australia (R.H.R.) Division of Endocrinology and Metabolism (E.D.A.), ...

A joint research group team led by Sayuri Tsukahara and Tetsuji Kakutani of the University of Tokyo has clarified a mechanism of how retrotransposons, genetic elements that can "jump around ...

Scientists investigating Alzheimer’s disease have made a key breakthrough, identifying a vital cellular mechanism driving the most common cause of dementia. The research from the City University ...

The infusion rate should be reduced by 50% in case of nonserious infusion reactions In patients who develop serious infusion reactions, cetuximab should be discontinued immediately and permanently ...